Molecular Testing in CML between Old and New Methods: Are We at a Turning Point?

Exosomes in Chronic Myeloid Leukemia: Are We Reading a New Reliable Message?

(2020) Simona Bernardi et al.   ACTA HAEMATOLOGICA

Detection of Actionable BCR-ABL1 Kinase Domain (KD) Mutations in Chronic Myeloid Leukemia (CML) Patients with Failure and Warning Response to Tyrosine Kinase Inhibitors (TKIs): Potential Impact of Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR) on Clinical Decision Making

(2020) Simona Soverini et al.   BLOOD

Detection of T315I using digital polymerase chain reaction in allogeneic transplant recipients with Ph-positive acute lymphoblastic anemia in the dasatinib era

(2020) Yu Akahoshi et al.   EXPERIMENTAL HEMATOLOGY

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

(2020) A. Hochhaus et al.   LEUKEMIA

Highly Sensitive Detection of IDH2 Mutations in Acute Myeloid Leukemia

(2020) Jessica Petiti et al.   Journal of Clinical Medicine

Digital PCR: A Reliable Tool for Analyzing and Monitoring Hematologic Malignancies

(2020) Nicoletta Coccaro et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances

(2020) Cosimo Cumbo et al.   Cancer Management and Research

Digital Droplet PCR is a Specific and Sensitive Tool for Detecting IDH2 Mutations in Acute Myeloid LeuKemia Patients

(2020) Susanna Grassi et al.   Cancers

Isolation of extracellular vesicles improves the detection of mutant DNA from plasma of metastatic melanoma patients

(2020) Davide Zocco et al.   Scientific Reports

The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview

(2019) Michele Baccarani et al.   LEUKEMIA

Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials

(2019) Birgit Spiess et al.   PLoS One

A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib

(2019) Hiroaki Kitamura et al.   PLoS One

Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis

(2019) Jesus G. Berdeja et al.   LEUKEMIA & LYMPHOMA

Variant‐specific discrepancy when quantitating BCR‐ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay

(2019) Lasse Kjaer et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Digital PCR in Myeloid Malignancies: Ready to Replace Quantitative PCR?

(2019) Daniela Cilloni et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Analytical Validation of a Highly Sensitive, Multiplexed Chronic Myeloid Leukemia Monitoring System Targeting BCR-ABL1 RNA

(2019) Justin T. Brown et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia

(2019) Irene Della Starza et al.   LEUKEMIA & LYMPHOMA

Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation

(2019) Simona Bernardi et al.   Cancer Medicine

Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study

(2019) Aytug Kizilors et al.   Lancet Haematology

Recommandations du France Intergroupe des leucémies myéloïdes chroniques (Fi-LMC) pour l’examen des mutations du domaine kinase de BCR-ABL1 dans la leucémie myéloïde chronique

(2019) Jean-Michel Cayuela et al.   BULLETIN DU CANCER

Evaluation of residual disease and TKI duration are predictive factors for molecular recurrence after stopping Imatinib first-line in chronic phase CML Patients

(2019) Franck Emmanuel Nicolini et al.   CLINICAL CANCER RESEARCH

“Variant‐specific discrepancy when quantitating BCR‐ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay.” Is dPCR the key?

(2019) Simona Bernardi et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Large amplicon droplet digital PCR for DNA‐based monitoring of pediatric chronic myeloid leukaemia

(2019) Manuela Krumbholz et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia

(2019) Susan Branford et al.   LEUKEMIA

Monitoring Chronic Myeloid Leukemia: How Molecular Tools May Drive Therapeutic Approaches

(2019) Barbara Izzo et al.   Frontiers in Oncology

Conventional Real Time Quantitative Polymerase Chain Reaction Method Yields Similar Level of Sensitivity to Digital Droplet Polymerase Chain Reaction for Detection of BCR-ABL p210 Transcripts in Patients with Chronic Phase Chronic Myeloid Leukemia

(2019) Hannah Asghari et al.   BLOOD

Droplet Digital PCR Phasing (DROP-PHASE): A Novel Method for Straightforward Detection of BCR-ABL1 Compound Mutations in Tyrosine Kinase Inhibitors Resistant Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL)

(2019) Pascal Vannuffel et al.   BLOOD

Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia

(2019) Simona Bernardi et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study

(2019) Simona Soverini et al.   BLOOD

Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper

(2019) Simona Soverini et al.   Journal of Hematology & Oncology

Comparison of Real-Time Quantitative PCR and Digital Droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid Leukemia

(2019) Georg-Nikolaus Franke et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Precision cancer monitoring using a novel, fully integrated, microfluidic array partitioning digital PCR platform

(2019) Megan E. Dueck et al.   Scientific Reports

Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high risk disease

(2018) Susan Branford et al.   BLOOD

Droplet digital PCR for BCR/ABL(P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression

(2018) Wen-Jun Wang et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Highly sensitive MYD88 L265P mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemia

(2018) Daniela Drandi et al.   HAEMATOLOGICA

Monitoring of clonal evolution of double C-KIT exon 17 mutations by Droplet Digital PCR in patients with core-binding factor acute myeloid leukemia

(2018) Yanhong Tan et al.   LEUKEMIA RESEARCH

Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy

(2018) Simona Soverini et al.   Molecular Cancer

dPCR: A Technology Review

(2018) Phenix-Lan Quan et al.   SENSORS

Genomic BCR-ABL1 breakpoint characterization by a multi-strategy approach for “personalized monitoring” of residual disease in chronic myeloid leukemia patients

(2018) Cosimo Cumbo et al.   Oncotarget

Highly sensitive MYD88 L265P mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemia

(2018) Daniela Drandi et al.   HAEMATOLOGICA

Optimized Digital Droplet PCR for BCR-ABL

(2018) Jacqueline Maier et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Mutational analysis in BCR - ABL1 positive leukemia by deep sequencing based on nanopore MinION technology

(2017) Crescenzio F. Minervini et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia

(2017) Alice Giustacchini et al.   NATURE MEDICINE

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants

(2016) Simona Soverini et al.   BMC CANCER

Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia

(2016) C. Baer et al.   HAEMATOLOGICA

Chronic myelogenous leukaemia exosomes modulate bone marrow microenvironment through activation of epidermal growth factor receptor

(2016) Chiara Corrado et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients

(2016) Simona Soverini et al.   Oncotarget

Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia

(2016) C. Baer et al.   HAEMATOLOGICA

The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia

(2016) Francesca Guerrini et al.   Frontiers in Pharmacology

Validation of a rapid one-step high sensitivity real-time quantitative PCR system for detecting major BCR-ABL1 mRNA on an International Scale

(2016) Chikashi Yoshida et al.   SpringerPlus

Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study

(2015) Silvia Mori et al.   AMERICAN JOURNAL OF HEMATOLOGY

Initial diagnosis of chronic myelogenous leukemia based on quantification of M-BCR status using droplet digital PCR

(2015) Helen Louise Lund et al.   ANALYTICAL AND BIOANALYTICAL CHEMISTRY

Real-Time PCR and Droplet Digital PCR: two techniques for detection of theJAK2V617Fmutation in Philadelphia-negative chronic myeloproliferative neoplasms

(2015) G. Fontanelli et al.   International Journal of Laboratory Hematology

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia

(2015) N C P Cross et al.   LEUKEMIA

Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment

(2015) D Russo et al.   Blood Cancer Journal

BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia

(2014) Matthew S. Zabriskie et al.   CANCER CELL

Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase

(2014) Katerina Machova Polakova et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

(2013) M. Baccarani et al.   BLOOD

Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain

(2013) S. Soverini et al.   BLOOD

Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia

(2012) Manuela Krumbholz et al.   GENES CHROMOSOMES & CANCER

Study of polymorphism in imatinib mesylate: A quantum chemical approach using electronic and vibrational spectra

(2012) Anubha Srivastava et al.   SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

(2011) S. Soverini et al.   BLOOD

Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay

(2011) Hyun-Gyung Goh et al.   LEUKEMIA & LYMPHOMA